BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 28609655)

  • 21. The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia.
    Baker A; Gregory GP; Verbrugge I; Kats L; Hilton JJ; Vidacs E; Lee EM; Lock RB; Zuber J; Shortt J; Johnstone RW
    Cancer Res; 2016 Mar; 76(5):1158-69. PubMed ID: 26627013
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MLL1 and DOT1L cooperate with meningioma-1 to induce acute myeloid leukemia.
    Riedel SS; Haladyna JN; Bezzant M; Stevens B; Pollyea DA; Sinha AU; Armstrong SA; Wei Q; Pollock RM; Daigle SR; Jordan CT; Ernst P; Neff T; Bernt KM
    J Clin Invest; 2016 Apr; 126(4):1438-50. PubMed ID: 26927674
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Cks1/Cks2 axis fine-tunes Mll1 expression and is crucial for MLL-rearranged leukaemia cell viability.
    Grey W; Ivey A; Milne TA; Haferlach T; Grimwade D; Uhlmann F; Voisset E; Yu V
    Biochim Biophys Acta Mol Cell Res; 2018 Jan; 1865(1):105-116. PubMed ID: 28939057
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The SUMO-specific isopeptidase SENP3 regulates MLL1/MLL2 methyltransferase complexes and controls osteogenic differentiation.
    Nayak A; Viale-Bouroncle S; Morsczeck C; Muller S
    Mol Cell; 2014 Jul; 55(1):47-58. PubMed ID: 24930734
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mechanisms of transformation by MLL.
    Hess JL
    Crit Rev Eukaryot Gene Expr; 2004; 14(4):235-54. PubMed ID: 15663355
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pygo2 functions as a prognostic factor for glioma due to its up-regulation of H3K4me3 and promotion of MLL1/MLL2 complex recruitment.
    Zhou C; Zhang Y; Dai J; Zhou M; Liu M; Wang Y; Chen XZ; Tang J
    Sci Rep; 2016 Feb; 6():22066. PubMed ID: 26902498
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MLL-rearranged acute myeloid leukemia: Influence of the genetic partner in allo-HSCT response and prognostic factor of MLL 3' region mRNA expression.
    Burillo-Sanz S; Morales-Camacho RM; Caballero-Velázquez T; Carrillo E; Sánchez J; Pérez-López O; Pérez de Soto I; González Campos J; Prats-Martín C; Bernal R; Vargas MT
    Eur J Haematol; 2018 May; 100(5):436-443. PubMed ID: 29384595
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential regulation of the c-Myc/Lin28 axis discriminates subclasses of rearranged MLL leukemia.
    Chen L; Sun Y; Wang J; Jiang H; Muntean AG
    Oncotarget; 2016 May; 7(18):25208-23. PubMed ID: 27007052
    [TBL] [Abstract][Full Text] [Related]  

  • 29. COMPASS Ascending: Emerging clues regarding the roles of MLL3/KMT2C and MLL2/KMT2D proteins in cancer.
    Fagan RJ; Dingwall AK
    Cancer Lett; 2019 Aug; 458():56-65. PubMed ID: 31128216
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia.
    Dafflon C; Craig VJ; Méreau H; Gräsel J; Schacher Engstler B; Hoffman G; Nigsch F; Gaulis S; Barys L; Ito M; Aguadé-Gorgorió J; Bornhauser B; Bourquin JP; Proske A; Stork-Fux C; Murakami M; Sellers WR; Hofmann F; Schwaller J; Tiedt R
    Leukemia; 2017 Jun; 31(6):1269-1277. PubMed ID: 27840424
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Murine Retrovirally-Transduced Bone Marrow Engraftment Models of MLL-Fusion-Driven Acute Myelogenous Leukemias (AML).
    Stubbs MC; Krivtsov AV
    Curr Protoc Pharmacol; 2017 Sep; 78():14.42.1-14.42.19. PubMed ID: 28892146
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recurrent
    Matsuo H; Yoshida K; Fukumura K; Nakatani K; Noguchi Y; Takasaki S; Noura M; Shiozawa Y; Shiraishi Y; Chiba K; Tanaka H; Okada A; Nannya Y; Takeda J; Ueno H; Shiba N; Yamato G; Handa H; Ono Y; Hiramoto N; Ishikawa T; Usuki K; Ishiyama K; Miyawaki S; Itonaga H; Miyazaki Y; Kawamura M; Yamaguchi H; Kiyokawa N; Tomizawa D; Taga T; Tawa A; Hayashi Y; Mano H; Miyano S; Kamikubo Y; Ogawa S; Adachi S
    Blood Adv; 2018 Nov; 2(21):2879-2889. PubMed ID: 30381403
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia.
    Feng Z; Yao Y; Zhou C; Chen F; Wu F; Wei L; Liu W; Dong S; Redell M; Mo Q; Song Y
    J Hematol Oncol; 2016 Mar; 9():24. PubMed ID: 26970896
    [TBL] [Abstract][Full Text] [Related]  

  • 34. TGIF1 is a negative regulator of MLL-rearranged acute myeloid leukemia.
    Willer A; Jakobsen JS; Ohlsson E; Rapin N; Waage J; Billing M; Bullinger L; Karlsson S; Porse BT
    Leukemia; 2015 May; 29(5):1018-31. PubMed ID: 25349154
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: a study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group.
    Gröschel S; Schlenk RF; Engelmann J; Rockova V; Teleanu V; Kühn MW; Eiwen K; Erpelinck C; Havermans M; Lübbert M; Germing U; Schmidt-Wolf IG; Beverloo HB; Schuurhuis GJ; Ossenkoppele GJ; Schlegelberger B; Verdonck LF; Vellenga E; Verhoef G; Vandenberghe P; Pabst T; Bargetzi M; Krauter J; Ganser A; Valk PJ; Löwenberg B; Döhner K; Döhner H; Delwel R
    J Clin Oncol; 2013 Jan; 31(1):95-103. PubMed ID: 23008312
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular pathogenesis of disease progression in MLL-rearranged AML.
    Kotani S; Yoda A; Kon A; Kataoka K; Ochi Y; Shiozawa Y; Hirsch C; Takeda J; Ueno H; Yoshizato T; Yoshida K; Nakagawa MM; Nannya Y; Kakiuchi N; Yamauchi T; Aoki K; Shiraishi Y; Miyano S; Maeda T; Maciejewski JP; Takaori-Kondo A; Ogawa S; Makishima H
    Leukemia; 2019 Mar; 33(3):612-624. PubMed ID: 30209403
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The cancer COMPASS: navigating the functions of MLL complexes in cancer.
    Ford DJ; Dingwall AK
    Cancer Genet; 2015 May; 208(5):178-91. PubMed ID: 25794446
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relatively favorable prognosis for MLL-rearranged childhood acute leukemia with reciprocal translocations.
    Yang L; Ding L; Liang J; Chen J; Tang Y; Xue H; Gu L; Shen S; Li B; Chen J
    Pediatr Blood Cancer; 2018 Oct; 65(10):e27266. PubMed ID: 29943896
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structural basis of nucleosome recognition and modification by MLL methyltransferases.
    Xue H; Yao T; Cao M; Zhu G; Li Y; Yuan G; Chen Y; Lei M; Huang J
    Nature; 2019 Sep; 573(7774):445-449. PubMed ID: 31485071
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cell context in the control of self-renewal and proliferation regulated by MLL1.
    Artinger EL; Ernst P
    Cell Cycle; 2013 Sep; 12(18):2969-72. PubMed ID: 23974107
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.